Stock Traders Buy High Volume of Put Options on Omeros (NASDAQ:OMER)

Omeros Corporation (NASDAQ:OMER) saw unusually large options trading activity on Tuesday. Investors acquired 11,366 put options on the stock. This is an increase of 247% compared to the average daily volume of 3,275 put options.

Insider Buying and Selling at Omeros

In other news, Director Thomas J. Cable sold 7,500 shares of the business’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $11.61, for a total value of $87,075.00. Following the completion of the sale, the director owned 35,067 shares of the company’s stock, valued at approximately $407,127.87. The trade was a 17.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 10.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OMER. UBS Group AG lifted its stake in Omeros by 213.5% in the fourth quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock valued at $38,180,000 after buying an additional 1,513,893 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Omeros by 1,201.1% during the third quarter. JPMorgan Chase & Co. now owns 416,153 shares of the biopharmaceutical company’s stock worth $1,706,000 after acquiring an additional 384,168 shares during the last quarter. Corient Private Wealth LLC increased its holdings in shares of Omeros by 13.0% in the 4th quarter. Corient Private Wealth LLC now owns 688,025 shares of the biopharmaceutical company’s stock worth $11,817,000 after acquiring an additional 79,263 shares during the period. AlphaQuest LLC increased its holdings in shares of Omeros by 8,259,600.0% in the 4th quarter. AlphaQuest LLC now owns 82,597 shares of the biopharmaceutical company’s stock worth $1,419,000 after acquiring an additional 82,596 shares during the period. Finally, Vanguard Group Inc. lifted its position in Omeros by 19.9% in the 4th quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock valued at $68,929,000 after purchasing an additional 666,357 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Zacks Research upgraded Omeros from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 2nd. HC Wainwright cut their price objective on Omeros from $40.00 to $33.00 and set a “buy” rating on the stock in a research note on Friday, June 26th. Weiss Ratings downgraded Omeros from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, June 2nd. D. Boral Capital reiterated a “buy” rating and issued a $36.00 target price on shares of Omeros in a research report on Tuesday, April 21st. Finally, Wall Street Zen downgraded Omeros from a “buy” rating to a “hold” rating in a report on Sunday, June 7th. Two research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $38.00.

Omeros Price Performance

Shares of NASDAQ:OMER traded up $0.55 during trading on Tuesday, reaching $10.56. 476,041 shares of the company’s stock traded hands, compared to its average volume of 1,613,763. Omeros has a 12 month low of $3.34 and a 12 month high of $17.65. The company has a 50 day moving average of $11.04 and a 200-day moving average of $11.87. The stock has a market capitalization of $764.62 million, a P/E ratio of 15.07 and a beta of 2.55.

Omeros (NASDAQ:OMER) last released its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.16. The business had revenue of $9.89 million for the quarter, compared to analyst estimates of $4.19 million. Equities research analysts predict that Omeros will post -0.94 earnings per share for the current fiscal year.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.